Rivulet Entertainment, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rivulet Entertainment, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $10.00M | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | $60.0K | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | $0 | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.24M | Mar 28, 2014 |
| FY2012 | Dec 31, 2012 | $1.24M | Mar 5, 2013 |
| FY2011 | Dec 31, 2011 | $1.24M | Mar 12, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($468.3K) | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | $60.0K | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | $0 | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2013 | Dec 31, 2013 | $862.5K | Mar 28, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($5.92M) | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | ($181.5K) | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | ($310.9K) | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | ($48.6K) | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | ($83.4K) | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | ($81.5K) | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | ($68.3K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($67.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($92.6K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($76.8K) | Sep 24, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($4.03M) | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | ($181.5K) | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | ($354.3K) | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | ($46.6K) | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | ($81.1K) | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | ($76.8K) | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | ($66.6K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($58.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($82.3K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($65.9K) | Sep 24, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.19M | Mar 28, 2014 |
| FY2012 | Dec 31, 2012 | $1.19M | Mar 5, 2013 |
| FY2011 | Dec 31, 2011 | $1.19M | Mar 12, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.6K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $773 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $298 | Apr 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($10.98M) | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | ($9.46M) | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | ($348.2K) | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | ($46.5K) | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | ($44.4K) | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | ($33.0K) | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | ($56.2K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($75.6K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($60.1K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($44.3K) | Sep 24, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.1K | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Mar 27, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.81M | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | $13.03M | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | $1.4K | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $138 | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | $12.1K | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | $14.3K | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | $34.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $61.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $64.1K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $77.6K | Sep 24, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $26.31M | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | $18.06M | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | $350.2K | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $343.7K | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | $312.2K | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | $277.0K | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | $238.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $265.4K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $314.8K | Sep 24, 2018 |
| FY2017 | Dec 31, 2016 | $295.7K | Sep 24, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($6.50M) | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | ($5.03M) | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | ($348.8K) | Mar 27, 2024 |
| FY2025 | Jun 30, 2023 | ($4.85M) | Oct 15, 2025 |
| FY2022 | Dec 31, 2022 | ($343.6K) | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | ($300.0K) | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | ($262.6K) | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | ($203.7K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($204.4K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($250.7K) | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($10.95M) | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | ($5.03M) | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | ($8.94M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | ($8.63M) | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | ($8.58M) | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | ($8.50M) | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | ($8.42M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($8.35M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($8.28M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.19M) | Sep 24, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $128.1K | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | $480 | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $138 | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | $12.1K | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | $348 | Aug 25, 2022 |
| FY2021 | Dec 31, 2019 | $6.2K | Aug 25, 2022 |
| FY2020 | Dec 31, 2018 | $17.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $7.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $9.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $9.0K | Sep 24, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | 0 | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Sep 11, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Oct 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 109.70M | Oct 15, 2025 |
| FY2025 | Jun 30, 2024 | 96.72M | Oct 15, 2025 |
| FY2023 | Dec 31, 2023 | 5.48M | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | 547.50M | Sep 11, 2024 |
| FY2022 | Dec 31, 2021 | 284.59M | Sep 11, 2024 |
| FY2021 | Dec 31, 2020 | 280.39M | Aug 25, 2022 |
| FY2020 | Dec 31, 2019 | 278.22M | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | 267.02M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 243.92M | Apr 1, 2019 |